Articles tagged with Endocrine Tumors
The European Society of Endocrinology is urging policy action to address a widening gap between care demand and workforce capacity. The endocrine workforce faces significant stress, burnout, and limited time for research, threatening timely and high-quality care.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
A Phase II clinical trial led by researchers at the University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma. Belzutifan showed a 26% objective response rate, with sustained clinical benefits for those who responded to treatment.
The European Society of Endocrinology has released the EndoCompass Research Roadmap, a major new initiative to align research efforts and improve funding strategies for hormone-related health challenges. The roadmap identifies specific research needs across eight endocrine specialties and five cross-cutting areas.
The EndoCompass project aims to guide future studies and funding programs with a research roadmap for better hormone health in Europe. Manuel Heitor will share his perspective on the future of research in Europe, emphasizing the need for greater investment and coordination.
The European Society of Endocrinology and the European Hormone and Metabolism Foundation launch a global campaign to raise awareness about hormone balance and its impact on chronic diseases. Small steps can make a big difference in improving hormone health.
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
The ESMO Sarcoma and Rare Cancers Congress 2025 will bring together experts to present and discuss developments in diagnosing and treating rare solid tumours. The event will focus on immunotherapy, global challenges, and opportunities for international collaboration.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
Dr. Reichlin's groundbreaking work on brain-hormone interactions and his influence on generations of endocrinologists are being celebrated through a Festschrift series in Brain Medicine. The series explores multiple facets of his contributions, including pioneering work on hypothalamic control of pituitary function and early recognitio...
The CABINET trial demonstrates that cabozantinib significantly improves median progression-free survival (PFS) for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The treatment also shows promise across all clinical subgroups, including primary tumor site and grade.
Researchers have developed a new model for studying pulmonary neuroendocrine tumors, which may indicate that patients with EGF-dependent NETs can be treated with EGF receptor inhibitors. This discovery provides a promising route of treatment for aggressive pulmonary NETs.
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
Scientists at CNIO identify succinylation as a poorly studied mechanism in cancer research; mutated DLST protein prevents succinylation, leading to pseudohypoxia and tumor growth. Succinylation is crucial for protein function and may be linked to various diseases.
Researchers have identified markers associated with an increased risk of metastasis in patients with metastatic pheochromocytoma, allowing for personalized clinical management. The study also identifies patients who could benefit from immunotherapy treatments, paving the way for potential new therapies.
A cross-sectional study of over 25,000 adults found that approximately 70% of identified adrenal tumors were nonfunctioning, regardless of participant's age. The prevalence of adrenal tumors increased with age, from 0.2% in young adults to 3.2% in older adults.
A study published in Nature Communications found that neuroendocrine tumors in the small intestine often originate from different cells with unique genetic mutations. This breakthrough challenges conventional wisdom on cancer development and highlights the importance of removing all detected tumors to prevent late relapses.
The FIRSTMAPPP trial found that sunitinib significantly prolongs progression-free survival in patients with malignant pheochromocytoma and paraganglioma. The study demonstrated the efficacy of sunitinib as a treatment option for this rare cancer, which is commonly treated with old and toxic agents.
Researchers are drawing attention to the rare disease due to its misdiagnosis. Caused by small benign tumors in the pituitary gland, it can lead to excessive weight gain, acne, and a lump on the back of the neck.
The Endocrine Society recommends blood and urine tests for metanephrines to identify patients with pheochromocytomas and paragangliomas, which can cause high blood pressure and cardiovascular disease. Genetic testing is also recommended for family members at risk, based on a shared decision-making process with physicians.
A multi-institutional team has discovered a gene mutation associated with several cancers also drives a rare brain tumor called papillary craniopharyngioma. The BRAF mutation was found in 94% of tested papillary tumors, suggesting it could be targeted by existing therapies.
The Endocrine Society released a new Clinical Practice Guideline for the evaluation and treatment of pituitary incidentalomas. The guideline recommends a complete history and physical examination, including visual field examinations if necessary, for patients with a pituitary incidentaloma.
Researchers have found a genetic cause for benign hormone-producing tumours in the adrenal gland that lead to high blood pressure. The mutation affects a potassium channel, resulting in excessive aldosterone production and elevated blood pressure.
Solid-pseudopapillary neoplasm (SPN) of the pancreas is characterized by cystic-solid tumors in young women, often with hemorrhage and necrosis. Immunohistochemistry helps differentiate it from pancreatic endocrine tumor (PET), which harbors distinct genetic mutations.
A recent study published in the November issue of Gastrointestinal Endoscopy found that six percent of asymptomatic women underwent endoscopic screening and were diagnosed with Barrett's esophagus. Additionally, researchers demonstrated the accuracy of EUS-FNA in diagnosing pancreatic endocrine tumors, predicting five-year survival rat...
Researchers developed a preoperative endocrine prognostic index (PEPI) to predict relapse risk in women with stage 2 or 3 estrogen receptor-positive breast cancer. The model incorporates tumor characteristics and is statistically significant in predicting relapse-free survival.
The NIH team identified the MEN1 gene, a tumor suppressor gene that inhibits abnormal cell growth. This discovery enables easier screening for families at risk of MEN1 and provides a target for designing drugs to prevent or treat endocrine tumors.